Stockscreener 앱 받기
22.50
2.13%
-0.49
Sarepta Therapeutics Inc 주식(SRPT)의 최신 뉴스
SRPT Stock Plunges 7% After-Hours As Elevidys Demand Slumps — CEO Still Sees Return To Growth - Stocktwits
SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling - Stocktwits
Sarepta Therapeutics Delivers Q2 Operating Profit as CEO Transition Advances Pipeline - Streetwise Reports
Sarepta Therapeutics Jumps 8.6% Amid Sector-Wide Rally - AlphaStreet
Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 9.2%Here's Why - MarketBeat
Sarepta Awaits New FDA Challenge as Trump Chooses Heidi Overton - TechStock²
SRPT|Sarepta Therapeutics Inc|Price:19.220|Chg%:-0.510 - TradingKey
Sarepta Therapeutics Stock Short Interest Falls to 31.28% - Quiver Quantitative
Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study - Stocktwits
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits
GSA Capital Partners LLP Purchases New Holdings in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: 22% Potential Upside Amidst Innovative Gene Therapy Developments - DirectorsTalk Interviews
Sarepta Posts US$328.7M Results - Streetwise Reports
Sarepta Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
SRPT6155802 Latest News and Headlines - TradingView
Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat - Stocktwits
Sarepta Therapeutics (NASDAQ:SRPT) Upgraded to "Hold" at Zacks Research - MarketBeat
Sarepta Therapeutics (SRPT) submits Form 13F showing one entry and $0 value - Stock Titan
Massachusetts Biotech's Flagship Gene Therapy Posts Fifth Straight Quarterly Decline as Muscular Dystrophy Data Loom - Streetwise Reports
Sarepta Therapeutics (SRPT) sees 5.05% ownership reported by AQR in 13G/A - Stock Titan
Bank of America Corp DE Increases Stock Position in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Therapeutics, Inc. (SRPT) Stock Forecasts - Yahoo Finance
Sarepta (SRPT) Q2 2026 Earnings Call Transcript - AOL.com
Assenagon Asset Management S.A. Makes New $8.16 Million Investment in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Dimensional Fund Advisors LP Sells 121,412 Shares of Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 - The National Law Review
Sarepta Therapeutics, Inc. (SRPT) Investor Outlook: Analyzing The 31.63% Potential Upside - DirectorsTalk Interviews
Why Sarepta Therapeutics (SRPT) Is Up 12.9% After Cutting 2026 Guidance And Naming A New CEO - simplywall.st
Sarepta Therapeutics, Inc. Revenue Breakdown – BX:AB3A - TradingView
Price to earnings forward of Sarepta Therapeutics, Inc. – BX:AB3A - TradingView
Sarepta Therapeutics (SRPT) Brings In Michael Severino As Chief Executive Officer - Sahm
Sarepta Therapeutics (NASDAQ:SRPT) Rating Lowered to "Hold" at Wall Street Zen - MarketBeat
(SRPT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
State Street (NYSE: STT) discloses 8.4% Sarepta Therapeutics ownership via Schedule 13G - Stock Titan
Traders Purchase Large Volume of Call Options on Sarepta Therapeutics (NASDAQ:SRPT) - MarketBeat
Wells Fargo Remains a Buy on Sarepta Therapeutics (SRPT) - The Globe and Mail
Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated - TradingView
Oppenheimer Adjusts PT on Sarepta Therapeutics to $35 From $37, Maintains Outperform Rating - marketscreener.com
Sarepta Therapeutics Navigates FDA Hold on Elevidys in Expanding DMD Market - Streetwise Reports
Empowered Funds LLC Has $2.48 Million Stake in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Is Sarepta Therapeutics Inc (SRPT) a Value Opportunity After Q2 Loss? GF Score: 63/100, Revenue at $401.3M - GuruFocus
Sarepta Therapeutics Inc (SRPT) (Q2 2026) Earnings Call Highligh - GuruFocus
Sarepta Therapeutics Q2 Earnings Call Highlights - MarketBeat
Sarepta Therapeutics Inc (SRPT) (Q2 2026) Earnings Call Highlights: Strong Profitability and ... - Yahoo Finance
Sarepta Therapeutics, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:SRPT) 2026-08-06 - Seeking Alpha
BlackRock, Inc. Adds to Sarepta Therapeutics Inc (SRPT) -- Shares Look 88% Undervalued on GF Value - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) Releases Quarterly Earnings Results, Beats Estimates By $0.42 EPS - marketbeat.com
Sarepta Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Earnings call transcript: Sarepta beats Q2 2026 estimates as shares rise after hours - Investing.com
Sarepta rises on quarterly double-line beat - Seeking Alpha
Sarepta Therapeutics: Q2 Earnings Snapshot - Barchart.com
Earnings Flash (SRPT) Sarepta Therapeutics, Inc. Posts Q2 Adjusted EPS $0.64 per Share - marketscreener.com
0.86%
0.31%
자본화:
|
볼륨(24시간):